Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19
Mukta Asnani, Katharina E. Hayer, Ammar S. Naqvi, et al.
Leukemia (2019) Vol. 34, Iss. 4, pp. 1202-1207
Open Access | Times Cited: 84

Showing 1-25 of 84 citing articles:

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
Jay Y. Spiegel, Shabnum Patel, Lori Muffly, et al.
Nature Medicine (2021) Vol. 27, Iss. 8, pp. 1419-1431
Open Access | Times Cited: 427
Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy
Tracy Rabilloud, Delphine Potier, Saran Pankaew, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 108
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells
Adam J. Lamble, Regina M. Myers, Agne Taraseviciute, et al.
Blood Advances (2022) Vol. 7, Iss. 4, pp. 575-585
Open Access | Times Cited: 95
Alternative splicing and related RNA binding proteins in human health and disease
Yining Tao, Qi Zhang, Haoyu Wang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 85
Advancing CAR T cell therapy through the use of multidimensional omics data
Jingwen Yang, Yamei Chen, Ying Jing, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 4, pp. 211-228
Closed Access | Times Cited: 66
Histone H3K9 Lactylation Confers Temozolomide Resistance in Glioblastoma via LUC7L2‐Mediated MLH1 Intron Retention
Yue Qu, Zhao Wang, Yixiong Shen, et al.
Advanced Science (2024) Vol. 11, Iss. 19
Open Access | Times Cited: 43
Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies
Yan-Ruide Li, Tyler Halladay, Lili Yang
Journal of Biomedical Science (2024) Vol. 31, Iss. 1
Open Access | Times Cited: 26
Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity
John P. Murad, Dileshni Tilakawardane, Anthony K. Park, et al.
Molecular Therapy (2021) Vol. 29, Iss. 7, pp. 2335-2349
Open Access | Times Cited: 76
The EBMT/EHA CAR-T Cell Handbook
Nicolaus Kröger, John G. Gribben, Christian Chabannon, et al.
Springer eBooks (2022)
Closed Access | Times Cited: 58
A comprehensive long-read isoform analysis platform and sequencing resource for breast cancer
Diogo F. T. Veiga, Alex Nesta, Yuqi Zhao, et al.
Science Advances (2022) Vol. 8, Iss. 3
Open Access | Times Cited: 52
The function of alternative splicing in the proteome: rewiring protein interactomes to put old functions into new contexts
Peter Kjer-Hansen, Robert J. Weatheritt
Nature Structural & Molecular Biology (2023) Vol. 30, Iss. 12, pp. 1844-1856
Closed Access | Times Cited: 28
Alternative splicing of its 5′-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies
Zhiwei Ang, Luca Paruzzo, Katharina E. Hayer, et al.
Blood (2023) Vol. 142, Iss. 20, pp. 1724-1739
Open Access | Times Cited: 24
CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Ugo Testa, Simona Sica, Elvira Pelosi, et al.
Mediterranean Journal of Hematology and Infectious Diseases (2024) Vol. 16, Iss. 1, pp. e2024010-e2024010
Open Access | Times Cited: 10
Beyond the storm — subacute toxicities and late effects in children receiving CAR T cells
Haneen Shalabi, Juliane Gust, Agne Taraseviciute, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 6, pp. 363-378
Open Access | Times Cited: 55
Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies
Sisi Zheng, Elisabeth Gillespie, Ammar S. Naqvi, et al.
Blood Cancer Discovery (2021) Vol. 3, Iss. 2, pp. 103-115
Open Access | Times Cited: 49
Isoform Age - Splice Isoform Profiling Using Long-Read Technologies
Ricardo De Paoli‐Iseppi, Josie Gleeson, Michael B. Clark
Frontiers in Molecular Biosciences (2021) Vol. 8
Open Access | Times Cited: 47
High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling CD19 splicing and CART-19 therapy resistance
Mariela Cortés-López, Laura Schulz, Monica Enculescu, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 30
Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency
Sarah Aminov, Orsi Giricz, David T. Melnekoff, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 8
Open Access | Times Cited: 8
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results
Liora M. Schultz, Nikeshan Jeyakumar, Anne Marijn Kramer, et al.
Leukemia (2024) Vol. 38, Iss. 5, pp. 963-968
Open Access | Times Cited: 8
The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B‐cell malignancies
Helena Brillembourg, Núria Martínez‐Cibrián, Mireia Bachiller, et al.
British Journal of Haematology (2024) Vol. 204, Iss. 5, pp. 1649-1659
Open Access | Times Cited: 7
A bibliometric and knowledge-map study on the treatment of hematological malignancies with CAR-T cells from 2012 to 2023
Qing Huang, Huimin Li, Yuan Zhang
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 7
Steering research on mRNA splicing in cancer towards clinical translation
Olga Anczuków, Frédéric H.‐T. Allain, Brittany Angarola, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 12, pp. 887-905
Closed Access | Times Cited: 7
Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope
Alejandrina Hernández-López, Mario A. Téllez-González, Paul Mondragón‐Terán, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 39
Exploiting Single-Cell Tools in Gene and Cell Therapy
Daniel Bode, Alyssa Cull, Juan Rubio‐Lara, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 34
Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches
Tianning Gu, Meng Zhu, He Huang, et al.
Journal of Zhejiang University SCIENCE B (2022) Vol. 23, Iss. 10, pp. 793-811
Open Access | Times Cited: 24
Page 1 - Next Page

Scroll to top